Skip to main content
Signal8
Launch Terminal

Autolus Therapeutics plc (AUTL)

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Autolus Therapeutics plc logo

Autolus Therapeutics plc

NASDAQ:AUTLHealthcare
-3.80%$1.52
AH$1.51-0.62%vs close
Mkt Cap$404.57M
Float218.05M
O/S266.16M
Vol
$ Vol
RVOL
Inst Own49.7%
Earnings
Dilution
Autolus Therapeutics plc logoNASDAQ:AUTL$1.52-3.80%
Phase Distribution
11 lead-sponsored trials·6 active·1 completed
Phase 13
Phase 1/25
Phase 22
Not applicable1
(2 more as collaborator)
Status Overview
Recruiting4
Active, not recruiting2
Completed1
Stopped3
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Enrolling by invitation

    Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

    AUTO CAR T cell therapy

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma +3

    Enrollment
    500
    Start
    Aug 2018
    Primary Completion
    Jul 2043est.
    Completion
    Dec 2043est.
    NCT03628612
  • Phase 2
    Recruiting

    Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

    Obecabtagene autoleucel

    Lupus Nephritis

    Enrollment
    35
    Start
    Jan 2026
    Primary Completion
    Aug 2028est.
    Completion
    Oct 2029est.
    NCT07053800
  • Phase 1/2
    Terminated

    APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

    AUTO2

    Multiple Myeloma

    Enrollment
    12
    Start
    May 2017
    Primary Completion
    Sep 2019
    Completion
    Sep 2019
    NCT03287804
  • Phase 1/2
    Terminated

    Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

    AUTO3

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Enrollment
    52
    Start
    Sep 2017
    Primary Completion
    Oct 2023
    Completion
    Oct 2023
    NCT03287817
  • Phase 1/2
    Completed

    CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

    AUTO3 (CD19/22 CAR T cells

    B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia +2

    Enrollment
    23
    Start
    Jun 2017
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT03289455
  • Phase 1/2
    Terminated

    Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma

    AUTO4

    T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified +2

    Enrollment
    20
    Start
    Aug 2018
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT03590574
  • Phase 1/2
    Active, not recruiting

    A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

    AUTO1

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    Enrollment
    153
    Start
    Jun 2020
    Primary Completion
    Jun 2029est.
    Completion
    Jun 2029est.
    NCT04404660
  • Phase 1
    Recruiting

    A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    AUTO1

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

    Enrollment
    30
    Start
    Nov 2023
    Primary Completion
    Nov 2027est.
    Completion
    Nov 2027est.
    NCT06173518
  • Phase 1
    Active, not recruiting

    Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

    Obecabtagene autoleucel (obe-cel)

    Systemic Lupus Erythematosus

    Enrollment
    16
    Start
    Feb 2024
    Primary Completion
    Sep 2027est.
    Completion
    Sep 2027est.
    NCT06333483
  • Phase 1
    Recruiting

    Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

    Obecabtagene autoleucel (obe-cel)

    Progressive Multiple Sclerosis

    Enrollment
    24
    Start
    Aug 2025
    Primary Completion
    Aug 2029est.
    Completion
    Aug 2029est.
    NCT07139743
  • Expanded access
    Available

    Expanded Access Program for OOS Obe-cel

    Out-of-specification obecabtagene autoleucel

    Lymphoblastic Leukemia, Acute, Adult, B Cell ALL

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT06799221
Search ClinicalTrials.gov for “Autolus Therapeutics”